# Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Thomas Grinda, Elie Rassy, Barbara Pistilli

► To cite this version:

Thomas Grinda, Elie Rassy, Barbara Pistilli. Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead. Current Treatment Options in Oncology, 2023, 24 (5), pp.466 - 467. 10.1007/s11864-023-01092-1. inserm-04564114

HAL Id: inserm-04564114

https://inserm.hal.science/inserm-04564114

Submitted on 30 Apr 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Thomas Grinda, Elie Rassy, Barbara Pistilli

► To cite this version:

Thomas Grinda, Elie Rassy, Barbara Pistilli. Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead. Current Treatment Options in Oncology, 2023, 24 (5), pp.466 - 467. 10.1007/s11864-023-01092-1. inserm-04564114

HAL Id: inserm-04564114

https://inserm.hal.science/inserm-04564114v1

Submitted on 30 Apr 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Thomas Grinda, MD*

Elie Rassy, MD†

Barbara Pistilli, MD*

**Address**

*Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant,

94800 Villejuif, France

Email: barbara.pistilli@gustaveroussy.fr

Published online: 18 April 2023

© The Author(s) 2023

The original article can be found online at https://doi.org/10.1007/s11864-023-01072-5.

Correction to: Current Treatment Options in Oncology
https://doi.org/10.1007/s11864-023-01072-5

The article "Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead", written by Thomas Grinda, Elie Rassy, and Barbara Pistilli, was originally published electronically on the publisher's internet portal on March 25, 2023 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on March 30, 2023 to © Authors 2023 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
# Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Thomas Grinda, MD*

Elie Rassy, MD†

Barbara Pistilli, MD*

**Address**

*Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant,

94800 Villejuif, France

Email: barbara.pistilli@gustaveroussy.fr

Published online: 18 April 2023

© The Author(s) 2023

The original article can be found online at https://doi.org/10.1007/s11864-023-01072-5.

Correction to: Current Treatment Options in Oncology
https://doi.org/10.1007/s11864-023-01072-5

The article "Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead", written by Thomas Grinda, Elie Rassy, and Barbara Pistilli, was originally published electronically on the publisher's internet portal on March 25, 2023 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on March 30, 2023 to © Authors 2023 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.